Stock VRP VERONA PHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Verona Pharma plc London S.E.

Equities

VRP

GB00BYW2KH80

Delayed London S.E.
Other stock markets
 12:35:15 2020-10-29 pm EDT 		5-day change 1st Jan Change
55 GBX +5.77% Intraday chart for Verona Pharma plc +4.76% -11.29%
Apr. 22 European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading MT
Apr. 16 European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT

Evolution of the average Target Price on Verona Pharma plc

Price target over the last 5 years

History of analyst recommendation changes

f.YM30URzGrIAK9RbyoQBmCX5eZbDorM03T7M_kSOT5Fc.D5SlAFSqwupOhVm063AnOSEqUueAmo9xOvJI8milvmcWrJkOSfXe1F-SdQ~4874da848acb2c9cad1e888a419891d4

Analyst Recommendations on Verona Pharma plc

Piper Sandler Raises Verona Pharma's Price Target to $36 From $31, Keeps Overweight Rating MT
Wedbush Raises Verona Pharma Price Target to $33 From $30, Maintains Outperform Rating MT
Truist Securities Adjusts Price Target on Verona Pharma to $32 From $28, Maintains Buy Rating MT
Possibility of US Fed's Rate Hike Pause Supports American Depositary Receipts of European Equities MT
BTIG Adjusts Price Target on Verona Pharma to $31 From $26, Maintains Buy Rating MT
European Equities Move Lower Following ECB Rate Hike MT
HC Wainwright Adjusts Verona Pharma's Price Target to $32 From $30, Keeps Buy Rating MT
Wedbush Raises Verona Pharma's Price Target to $30 From $23, Maintains Outperform Rating MT
Truist Securities Adjusts Price Target on Verona Pharma to $28 From $20, Maintains Buy Rating MT
BTIG Boosts Price Target on Verona Pharma to $26 From $17, Reiterates Buy Rating MT
ECB, Bank of England Interest Rate Hikes Weigh Down European Equities MT
Wedbush Lowers Verona Pharma's Price Target to $23 From $27 Due to Increased Share Count, Keeps Outperform Rating MT
Wedbush Analyst Assumes Coverage on Verona Pharma at Outperform With $27 Price Target, Up From $23 MT
HC Wainwright Adjusts Verona Pharma's Price Target to $30 From $25, Reiterates Buy Rating MT
Piper Sandler Initiates Coverage on Verona Pharma With Overweight Rating, $31 Price Target MT
Wedbush Raises Verona Pharma's Price Target to $23 From $18, Maintains Outperform Rating MT
Wedbush Cuts Verona Pharma's Price Target to $18 From $25, Adjusting Ensifentrine Launch Estimates; Outperform Rating Kept MT
Canaccord Genuity Adjusts Price Target on Verona Pharma to $23 From $18, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.47 USD
Average target price
34.29 USD
Spread / Average Target
+121.63%
High Price Target
38 USD
Spread / Highest target
+145.64%
Low Price Target
32 USD
Spread / Lowest Target
+106.85%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Verona Pharma plc

Piper Sandler
Wedbush
Truist Securities
BTIG
HC Wainwright
Canaccord Genuity

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VRNA Stock
  4. VRP Stock
  5. Consensus Verona Pharma plc